Use of a ghrelin agonist to improve the catabolic effects of glucocorticoid treatment
US8076281B2 · kind B2 · utility
5Cited by
2References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 10, 2008 |
| Grant date | Dec 13, 2011 |
| Priority date | — |
| Expiry date | Sep 4, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P19/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib2, Glu3(NH-hexyl)]hGhrelin(1-28)-NH2 (SEQ ID NO:2) or other suitable ghrelin agonist, to counteract the catabolic effects of said dexamethasone and other natural glucocorticoids.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.